190 related articles for article (PubMed ID: 22487056)
1. PEGylation of supercooled smectic cholesteryl myristate nanoparticles.
Mengersen F; Bunjes H
Eur J Pharm Biopharm; 2012 Jun; 81(2):409-17. PubMed ID: 22487056
[TBL] [Abstract][Full Text] [Related]
2. Influence of preparation conditions and heat treatment on the properties of supercooled smectic cholesteryl myristate nanoparticles.
Kuntsche J; Bunjes H
Eur J Pharm Biopharm; 2007 Nov; 67(3):612-20. PubMed ID: 17574399
[TBL] [Abstract][Full Text] [Related]
3. Influence of stabilizer systems on the properties and phase behavior of supercooled smectic nanoparticles.
Kuntsche J; Koch MH; Steiniger F; Bunjes H
J Colloid Interface Sci; 2010 Oct; 350(1):229-39. PubMed ID: 20619846
[TBL] [Abstract][Full Text] [Related]
4. Crystallization behavior of supercooled smectic cholesteryl myristate nanoparticles containing phospholipids as stabilizers.
Kuntsche J; Koch MH; Drechsler M; Bunjes H
Colloids Surf B Biointerfaces; 2005 Jul; 44(1):25-35. PubMed ID: 15990283
[TBL] [Abstract][Full Text] [Related]
5. Chemical stability of phospholipid-stabilized supercooled smectic cholesteryl myristate nanoparticles.
Mengersen F; Bunjes H
Eur J Pharm Biopharm; 2012 Oct; 82(2):262-71. PubMed ID: 22750438
[TBL] [Abstract][Full Text] [Related]
6. Supercooled smectic nanoparticles: influence of the matrix composition and in vitro cytotoxicity.
Kuntsche J; Koch MH; Fahr A; Bunjes H
Eur J Pharm Sci; 2009 Oct; 38(3):238-48. PubMed ID: 19664705
[TBL] [Abstract][Full Text] [Related]
7. Supercooled smectic nanoparticles: a potential novel carrier system for poorly water soluble drugs.
Kuntsche J; Westesen K; Drechsler M; Koch MH; Bunjes H
Pharm Res; 2004 Oct; 21(10):1834-43. PubMed ID: 15553230
[TBL] [Abstract][Full Text] [Related]
8. Poly(vinyl alcohol) as emulsifier stabilizes solid triglyceride drug carrier nanoparticles in the alpha-modification.
Rosenblatt KM; Bunjes H
Mol Pharm; 2009; 6(1):105-20. PubMed ID: 19049318
[TBL] [Abstract][Full Text] [Related]
9. The physical state of lipid nanoparticles influences their effect on in vitro cell viability.
Petersen S; Steiniger F; Fischer D; Fahr A; Bunjes H
Eur J Pharm Biopharm; 2011 Sep; 79(1):150-61. PubMed ID: 21458564
[TBL] [Abstract][Full Text] [Related]
10. Optimization, stabilization, and characterization of amphotericin B loaded nanostructured lipid carriers for ocular drug delivery.
Lakhani P; Patil A; Wu KW; Sweeney C; Tripathi S; Avula B; Taskar P; Khan S; Majumdar S
Int J Pharm; 2019 Dec; 572():118771. PubMed ID: 31669555
[TBL] [Abstract][Full Text] [Related]
11. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.
Kovacevic A; Savic S; Vuleta G; Müller RH; Keck CM
Int J Pharm; 2011 Mar; 406(1-2):163-72. PubMed ID: 21219990
[TBL] [Abstract][Full Text] [Related]
12. Physicochemical characterization of curcuminoid-loaded solid lipid nanoparticles.
Noack A; Hause G; Mäder K
Int J Pharm; 2012 Feb; 423(2):440-51. PubMed ID: 22197758
[TBL] [Abstract][Full Text] [Related]
13. Control over Particle Size Distribution by Autoclaving Poloxamer-Stabilized Trimyristin Nanodispersions.
Göke K; Roese E; Arnold A; Kuntsche J; Bunjes H
Mol Pharm; 2016 Sep; 13(9):3187-95. PubMed ID: 27463039
[TBL] [Abstract][Full Text] [Related]
14. Parenteral formulation of an antileishmanial drug candidate--tackling poor solubility, chemical instability, and polymorphism.
Kupetz E; Preu L; Kunick C; Bunjes H
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):511-20. PubMed ID: 23454203
[TBL] [Abstract][Full Text] [Related]
15. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery.
Liu CH; Wu CT; Fang JY
Drug Dev Ind Pharm; 2010 Jul; 36(7):751-61. PubMed ID: 20136495
[TBL] [Abstract][Full Text] [Related]
16. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.
Attama AA; Schicke BC; Paepenmüller T; Müller-Goymann CC
Eur J Pharm Biopharm; 2007 Aug; 67(1):48-57. PubMed ID: 17276663
[TBL] [Abstract][Full Text] [Related]
17. Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media.
Tho I; Liepold B; Rosenberg J; Maegerlein M; Brandl M; Fricker G
Eur J Pharm Sci; 2010 Apr; 40(1):25-32. PubMed ID: 20172027
[TBL] [Abstract][Full Text] [Related]
18. Molecular interaction and localization of tocotrienol-rich fraction (TRF) within the matrices of lipid nanoparticles: evidence studies by Differential Scanning Calorimetry (DSC) and Proton Nuclear Magnetic Resonance spectroscopy ((1)H NMR).
Ali H; El-Sayed K; Sylvester PW; Nazzal S
Colloids Surf B Biointerfaces; 2010 Jun; 77(2):286-97. PubMed ID: 20189780
[TBL] [Abstract][Full Text] [Related]
19. Stability of lipid excipients in solid lipid nanoparticles.
Radomska-Soukharev A
Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the drug loading capacity of different lipid nanoparticle dispersions by passive drug loading.
Rosenblatt KM; Bunjes H
Eur J Pharm Biopharm; 2017 Aug; 117():49-59. PubMed ID: 28315731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
